Current Patterns in the Epidemiology of Primary HIV Drug Resistance in North America and Europe
- 1 July 2004
- journal article
- review article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 9 (5) , 695-702
- https://doi.org/10.1177/135965350400900514
Abstract
Despite numerous studies in recent years, it is still difficult to draw general conclusions about the extent to which drug-resistant HIV-1 is transmitted. In addition to the highly stratified nature of primary resistance itself, true epidemiological surveillance has been rare and studies to date have suffered from wide variability in their designs, definitions and datasets. In the absence of consensus standards, this has resulted in a large number of isolated ‘snapshots’ with little scope for data-pooling and comparison. This brief review examines some of the major confounding factors that restrict the utility of individual studies and prevent the combination of studies to increase statistical power. Despite these limitations, data from North America and Europe lead to the tentative conclusion that transmission rates in these areas have generally fallen or remained stable in the past 2–3 years. However, data for the UK seem to indicate an ongoing rise in the transmission of drug resistance mutations, currently present in up to 20% of new infections. Transmission of resistant HIV represents a clinically important phenomenon, although the scale and relevance are being obscured by methodological variations and non-clinical definitions of resistance. Those of us with an interest in the epidemiology of drug resistance, whether in primary transmission or on-treatment, must learn to speak the same language if we are to establish meaningful correlations between survey datasets and the HIV-infected population as a whole.Keywords
This publication has 21 references indexed in Scilit:
- Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in MontrealAIDS, 2004
- Clinically Validated Genotype Analysis: Guiding Principles and Statistical ConcernsAntiviral Therapy, 2004
- Variable Prediction of Antiretroviral Treatment Outcome by Different Systems for Interpreting Genotypic Human Immunodeficiency Virus Type 1 Drug ResistanceThe Journal of Infectious Diseases, 2003
- Identification of a Transmission Chain of HIV Type 1 Containing Drug Resistance-Associated MutationsAIDS Research and Human Retroviruses, 2003
- Transmission Fitness of Drug‐Resistant Human Immunodeficiency Virus and the Prevalence of Resistance in the Antiretroviral‐Treated PopulationThe Journal of Infectious Diseases, 2003
- Antiretroviral-Drug Resistance among Patients Recently Infected with HIVNew England Journal of Medicine, 2002
- Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary InfectionJournal of Virology, 2002
- Analysis of prevalence of HIV-1 drug resistance in primary infections in the United KingdomBMJ, 2001
- Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable ViremiaNew England Journal of Medicine, 2001
- Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotypeAIDS, 1999